Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Recently, Zacks.com users have been paying close attention to Novavax (NVAX).

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and COVID-19 cases in the U.S. following the latest ...

Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup ... stopped short of adopting the “anti-vaxx” label attributed to him by critics.

Heightened awareness of H5N1 risks may boost demand for avian flu vaccines and related research initiatives. What Else: Novavax stands out for its non-mRNA approach to combating infectious diseases.

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it ...